Alam, January 14, 2016
This is the first Oncology API R&D Centre to be established in the ASEAN region. According to Mr. Junaid Waheed, CEO of Oncogen Pharma Sdn Bhd, it is a path breaking beginning in its vision and commitment of supplying high quality Oncology (Cancer) products that comply with all the stringent international regulatory requirements at affordable price to majority of cancer patients. These products will be researched, developed, patented in Malaysia and will then be supplied all over the world including U.S. and European markets.
Within 2016 itself, Oncogen Pharma Sdn Bhd will complete its Formulation Research and Development Centre based in Glenmarie. This will be followed by the construction of two Active Pharmaceutical Ingredient and Formulation Plants in the next 3 years. After the completion of these projects, Oncogen Pharma Sdn Bhd will have a fully integrated Oncology manufacturing establishment in Malaysia.
Oncogen Pharma Sdn Bhd has already acquired two pieces of industrial land in Bandar Enstek, Negri Sembilan, for both the plants. Basic designs for these two plants are already completed.
Malaysia was selected among many other countries due to its strategic importance in the region, ease of operations, quality of infrastructure and a talented pool of upcoming young scientists.
Mr. Junaid Waheed also highlighted the important role played by the Malaysian Investment Development Authority (MIDA) in convincing the Scitech Group to locate the project in Malaysia. Mr. Junaid further stated that when compared to the many countries in America, Europe, Middle East and Asia he has worked in, he finds that MIDA has very quickly grasped the vision of Oncogen Pharma and realised the pioneering nature of its projects. MIDA has facilitated Oncogen Pharma Sdn Bhd at every step whether it was regulatory, immigration or environmental compliances.The contribution of MIDA is one of the most significant ingredients in the success of Oncogen Pharma Sdn Bhd.
The vision of Oncogen Pharma Sdn Bhd is to develop and manufacture a niche, low-volume, high-potency products in US FDA approved plants. These are technology-intensive, hard-to-source products and the Company aims to be the first to market these products in the generic segment.The successful implementation of this integrated project will provide Malaysia a leading edge in the development of the Oncology pharmaceutical industry which will act as a catalyst in making Malaysia a hub for Oncology products.
Recruitment in Malaysia has started in order to take advantage of its talented pool of young and bright scientists. Recently recruited Malaysian scientists by the Company during the inaugration ceremony, highighted that the Company has given them the encouragement and opportunity to broaden their scope of learning a greenfield pharmaceutical technology and also the European and US FDA Pharmaceutical standards. The Company also intends to provide training to young Malaysian scientists in accordance with US and European standards and sponsor them for higher studies which will make them even better in their field. This will help Oncogen Pharma and the world to further help in reducing the prices of Oncolgy products to an affordable level.
“I am delighted that MIDA was able to play a role in facilitating this project that is in line with the country's focus on attracting higher value-added activities. We welcome Oncogen Pharma's R&D Centre as another proof of Malaysia's commitment to innovation. By investing millions and developing its workforce towards fulfilling its vision in providing affordable oncology products, Oncogen Pharma is a great example of how innovative companies can excel in Malaysia. Oncogen will be able to enjoy the market access to FTA network through the agreements that Malaysia has signed with many countries. Additionally, the company stands to benefit preferential access for its products from Malaysia’s potential Free Trade Agreements (FTAs) with the EU as well as the Trans-Pacific Partnership (TPP) member countries. More so, with the establishment of the ASEAN Economic Community and various ASEAN FTAs with China, Japan, India, Korea, Australia and New Zealand, the company has the option to further expand its export market to more than 3 billion people.,” said the CEO of MIDA.
“The R&D Centre, which will house a total of 35 Malaysian R&D staff, draws on the pool of talented young Malaysians to grow their operations. We are excited that the company has actively engaged with local universities such as University of Malaya (UM) for talent recruitment, participation in conference and R&D collaboration, and the development of its internship programme. In fact, Oncogen has hired 5 graduates from UM with Degrees and Masters in chemistry and biology related fields. From these engagements, I look forward to the more commercial outcomes from the excellent research happening in our universities," Dato’ Azman added.
For more information, please contact:
Mr. Joe Sian
Director, Oncogen Pharma (M) Sdn Bhd
012-2680359 / [email protected]
About Oncogen Pharma Sdn Bhd
Oncogen Pharma Sdn Bhd is a subsidiary of Scitech Group which is engaged in the research & development of APIs and Formulation and Manufacturing of Bulk Drugs for applications in the pharmaceutical industry across various therapeutic segments like anti-inflammatory, anticonvulsant, antihistaminic, antihypertensive etc. The Group’s existing R&D Centres and US FDA approved plants are located in India. Their products are currently sold in 30 countries. The Group has been established and operating for more than a decade with a vision to be the pioneer in the Pharmaceutical industry.